E Fund Management’s Apellis Pharmaceuticals APLS Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q2 | – | Sell |
-22,686
| Closed | -$913K | – | 493 |
|
|
2026
Q1 | $913K | Buy |
+22,686
| New | +$489K | 0.03% | 201 |
|
|
2025
Q2 | $278K | Sell |
16,057
-778
| -5% | -$14.4K | 0.01% | 323 |
|
|
2025
Q1 | $368K | Sell |
16,835
-327
| -2% | -$9.03K | 0.02% | 262 |
|
|
2024
Q4 | $548K | Buy |
17,162
+4,046
| +31% | +$122K | 0.03% | 216 |
|
|
2024
Q3 | $378K | Sell |
13,116
-1,580
| -11% | -$58.5K | 0.02% | 229 |
|
|
2024
Q2 | $564K | Buy |
14,696
+7,664
| +109% | +$347K | 0.03% | 166 |
|
|
2024
Q1 | $413K | Sell |
7,032
-625
| -8% | -$39.8K | 0.03% | 207 |
|
|
2023
Q4 | $458K | Sell |
7,657
-3,341
| -30% | -$169K | 0.03% | 177 |
|
|
2023
Q3 | $418K | Buy |
10,998
+6,035
| +122% | +$265K | 0.03% | 163 |
|
|
2023
Q2 | $452K | Sell |
4,963
-1,244
| -20% | -$107K | 0.04% | 127 |
|
|
2023
Q1 | $409K | Sell |
6,207
-2,397
| -28% | -$138K | 0.03% | 159 |
|
|
2022
Q4 | $445K | Buy |
8,604
+1,554
| +22% | +$82.4K | 0.04% | 155 |
|
|
2022
Q3 | $482K | Sell |
7,050
-3,601
| -34% | -$213K | 0.04% | 128 |
|
|
2022
Q2 | $482K | Buy |
10,651
+4,455
| +72% | +$203K | 0.04% | 147 |
|
|
2022
Q1 | $315K | Buy |
+6,196
| New | +$274K | 0.01% | 185 |
|
Other funds holding APLS
E Fund Management's APLS Position: Q2 2026 in Review
E Fund Management sold out of Apellis Pharmaceuticals (APLS) in Q2 2026, closing a stake of 22,686 shares — an estimated $913K sold.
E Fund Management first reported a position in APLS in Q1 2022 and held it in 15 quarters. The position peaked at $913K in Q1 2026. 1 fund tracked by Wall St. Rank holds APLS as of Q2 2026.
- E Fund Management reported no remaining Apellis Pharmaceuticals position as of Q2 2026 after selling out during the quarter.
- E Fund Management sold 22,686 Apellis Pharmaceuticals shares in Q2 2026, an estimated $913K.
- E Fund Management first reported a position in Apellis Pharmaceuticals in Q1 2022 and held it in 15 quarters.
- E Fund Management's Apellis Pharmaceuticals position peaked at $913K in Q1 2026.
- 1 fund tracked by Wall St. Rank held Apellis Pharmaceuticals as of Q2 2026.
Based on E Fund Management's 13F filing for Q2 2026, filed 11 Aug 2026.